18F-Radiolabeling and Preliminary Evaluation of a HSP90 ligand

Barrott, 2013, Hsp90, an unlikely ally in the war on cancer, FEBS J, 280, 1381, 10.1111/febs.12147 Biamonte, 2010, Heat shock protein 90: inhibitors in clinical trials, J Med Chem, 53, 3, 10.1021/jm9004708 Brough, 2008, 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer, J Med Chem, 51, 196, 10.1021/jm701018h Doi, 2014, Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors, Cancer Chemother Pharmacol, 74, 629, 10.1007/s00280-014-2521-x Dunphy, M. et al. First-in-human trial of Hsp90-targeted PET imaging. 53, 344-344 (2012). Eccles, 2008, NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis, Cancer Res, 68, 2850, 10.1158/0008-5472.CAN-07-5256 Jain, 2008, PEGylation: an approach for drug delivery. A review, Crit Rev Ther Drug Carrier Syst, 25, 403, 10.1615/CritRevTherDrugCarrierSyst.v25.i5.10 Kim, 2013, Effectively delivering a unique hsp90 inhibitor using star polymers, ACS Med Chem Lett, 4 Kimoto, 2017, Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In Vitro-In Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs, J Pharm Sci, 106, 2795, 10.1016/j.xphs.2017.04.043 Li, 2013, Current drug research on PEGylation with small molecular agents, Progress in Polymer Sciences, 38, 421, 10.1016/j.progpolymsci.2012.07.006 Mammatas, 2015, Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care, Cell Oncol (Dordr), 38, 49, 10.1007/s13402-014-0194-4 Mayer, 2012, Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors, Endocr Relat Cancer, 19, 217, 10.1530/ERC-11-0227 Schmidt, 2009, A modeling analysis of the effects of molecular size and binding affinity on tumor targeting, Mol Cancer Ther, 8, 2861, 10.1158/1535-7163.MCT-09-0195 Shrestha, 2016, (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease, Curr Top Med Chem, 16, 2753, 10.2174/1568026616666160413141911 Taldone, 2016, Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71, J Labelled Comp Radiopharm, 59, 129, 10.1002/jlcr.3369 Vermeulen, 2019, Evaluation of [(11)C]NMS-E973 as a PET tracer for in vivo visualisation of HSP90, Theranostics, 9, 554, 10.7150/thno.27213 Whitesell, 2012, Inhibiting HSP90 to treat cancer: a strategy in evolution, Curr Mol Med, 12, 1108, 10.2174/156652412803306657 Yuno, 2018, Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors, Methods Mol Biol, 1709, 423, 10.1007/978-1-4939-7477-1_29 Zitzmann, 2013, Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells, Int J Oncol, 43, 1824, 10.3892/ijo.2013.2130